search
Back to results

Combined Cingulate and Thalamic DBS for Chronic Refractory Chronic Pain (EMOPAIN)

Primary Purpose

Chronic Refractory Neuropathic Pain

Status
Active
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Deep brain Stimulation of cingulum anterior
Sponsored by
Centre Hospitalier Universitaire de Nice
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Chronic Refractory Neuropathic Pain

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • adult patients (age 18-70 years old) suffering from chronic (duration >1 year) unilateral neuropathic pain
  • severe (VAS score >6/10)
  • with high emotional impact (HAD subscores > 10) considered as resistant to medication specific to neuropathic pain at sufficient doses and durations (including at least antiepileptics and antidepressants) and not sufficiently improved by rTMS and relevant surgical solutions.

Non inclusion criteria:

  • previous history of stroke,
  • cognitive impairment (MMSE score <24),
  • DSMIV axis I psychiatric disorder,
  • contra-indication to surgery, anesthesia or MRI;
  • patient responder to rTMS,

Sites / Locations

  • Department of neurosurgery

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

DBS-ACC ON

DBS-ACC OFF

Arm Description

Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is ON and the second period, between M7 and M10 is OFF

Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is OFF and the second period, between M7 and M10 is ON

Outcomes

Primary Outcome Measures

Occurence of serious adverse events.
description of serious adverse events
Feasibility of ACC-DBS: success the process of surgical intervention
Feasibility of ACC-DBS will be evaluated by the proportion of patients undergoing with success the process of surgical intervention Safety will be evaluated by neurological examination
Feasibility of ACC-DBS : neurological success of the process of chronic stimulation
neurological success of the process of chronic stimulation will be evaluated by the neurological examination
Feasibility of ACC-DBS : psychiatric success of the process of chronic stimulation
psychiatric success of the process of chronic stimulation will be evaluated by the psychiatric assessment
Feasibility of ACC-DBS : cognitive success of the process of chronic stimulation
cognitive success of the process of chronic stimulation will be evaluated by the cognitive assessment

Secondary Outcome Measures

Efficacy of ACC-DBS : change of pain intensity
Efficacy of ACC-DBS will be evaluated by pain intensity (VAS)
Efficacy of ACC-DBS : change of pain intensity
Efficacy of ACC-DBS will be evaluated by pain intensity (Brief Pain Inventory)
Efficacy of ACC-DBS : change of pain intensity
Efficacy of ACC-DBS will be evaluated by pain intensity (McGill Pain Questionnaire)
Efficacy of ACC-DBS : change of quality of life by SF-36
Efficacy of ACC-DBS will be evaluated by quality of life (SF36).
Efficacy of ACC-DBS : change of quality of life by EQ-5D
Efficacy of ACC-DBS will be evaluated by quality of life (EQ5D).

Full Information

First Posted
December 1, 2017
Last Updated
July 19, 2023
Sponsor
Centre Hospitalier Universitaire de Nice
search

1. Study Identification

Unique Protocol Identification Number
NCT03399942
Brief Title
Combined Cingulate and Thalamic DBS for Chronic Refractory Chronic Pain
Acronym
EMOPAIN
Official Title
Treatment of Chronic Refractory Pain by Combined Deep Brain Stimulation of the Anterior Cingulum and Sensory Thalamus: a Feasibility and Safety Study
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 6, 2018 (Actual)
Primary Completion Date
March 20, 2024 (Anticipated)
Study Completion Date
March 20, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Nice

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Deep brain stimulation (DBS) of the sensory thalamus has been proposed for 40 years to treat medically refractory neuropathic pain, but its efficacy remains partial and unpredictable. Recently, bilateral DBS of the dorsal anterior cingulate cortex (ACC), a brain region involved in the integration of the affective and cognitive aspects of pain, has been successively proposed to treat few patients suffering from refractory chronic pain, by decreasing the emotional impact of their chronic pain. ACC-DBS could be an alternative or complementary approach to thalamic DBS in these patients, but the consequences of chronic dACC-DBS on cognition and affects have not been studied specifically. The primary objective is to evaluate the feasibility and safety of bilateral ACC-DBS combined with unilateral thalamic DBS in patients suffering from chronic unilateral pain, refractory to medical treatment. Secondary objective will evaluate the efficacy of this combined DBS compared to thalamic DBS only.
Detailed Description
Chronic pain represents a major personal and societal burden, especially for medically resistant patients. Deep brain stimulation (DBS) of the sensory thalamus has been proposed for 40 years to treat medically refractory neuropathic pain, but its efficacy remains partial and unpredictable. Recently, bilateral DBS of the dorsal anterior cingulate cortex (ACC), a brain region involved in the integration of the affective, emotional and cognitive aspects of pain, has been successively proposed to treat few patients suffering from refractory chronic pain. In a pilot study, 16 patients treated by ACC-DBS experienced a significant improvement of their quality of life despite a slight decrease of their pain intensity, by improving the affective and emotional impacts of their chronic pain. ACC-DBS could be an alternative or complementary approach to thalamic DBS in these patients. However the consequences of chronic dACC-DBS on cognition and affects have not been studied specifically. The primary objective of this study is to evaluate the feasibility and safety of bilateral ACC-DBS combined with unilateral thalamic DBS in patients suffering from chronic unilateral pain, refractory to medical treatment. Secondary objective will evaluate the efficacy of this combined DBS compared to thalamic DBS only

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Refractory Neuropathic Pain

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
DBS-ACC ON
Arm Type
Experimental
Arm Description
Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is ON and the second period, between M7 and M10 is OFF
Arm Title
DBS-ACC OFF
Arm Type
Experimental
Arm Description
Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is OFF and the second period, between M7 and M10 is ON
Intervention Type
Procedure
Intervention Name(s)
Deep brain Stimulation of cingulum anterior
Intervention Description
The Deep brain Stimulation of cingulum anterior is alternatively ON and OFF while Thalamic stimulation is ON
Primary Outcome Measure Information:
Title
Occurence of serious adverse events.
Description
description of serious adverse events
Time Frame
Day 0, Month 1, Month 4, Month 7, Month 10, Month 22
Title
Feasibility of ACC-DBS: success the process of surgical intervention
Description
Feasibility of ACC-DBS will be evaluated by the proportion of patients undergoing with success the process of surgical intervention Safety will be evaluated by neurological examination
Time Frame
Day 0
Title
Feasibility of ACC-DBS : neurological success of the process of chronic stimulation
Description
neurological success of the process of chronic stimulation will be evaluated by the neurological examination
Time Frame
Day 0, Month 1, Month 4, Month 7, Month 10, Month 22
Title
Feasibility of ACC-DBS : psychiatric success of the process of chronic stimulation
Description
psychiatric success of the process of chronic stimulation will be evaluated by the psychiatric assessment
Time Frame
Day 0, Month 1, Month 4, Month 7, Month 10, Month 22
Title
Feasibility of ACC-DBS : cognitive success of the process of chronic stimulation
Description
cognitive success of the process of chronic stimulation will be evaluated by the cognitive assessment
Time Frame
Day 0, Month 1, Month 4, Month 7, Month 10, Month 22
Secondary Outcome Measure Information:
Title
Efficacy of ACC-DBS : change of pain intensity
Description
Efficacy of ACC-DBS will be evaluated by pain intensity (VAS)
Time Frame
Day 0, Month 1, Month 4, Month 7, Month 10, Month 22
Title
Efficacy of ACC-DBS : change of pain intensity
Description
Efficacy of ACC-DBS will be evaluated by pain intensity (Brief Pain Inventory)
Time Frame
Day 0, Month 1, Month 4, Month 7, Month 10, Month 22
Title
Efficacy of ACC-DBS : change of pain intensity
Description
Efficacy of ACC-DBS will be evaluated by pain intensity (McGill Pain Questionnaire)
Time Frame
Day 0, Month 1, Month 4, Month 7, Month 10, Month 22
Title
Efficacy of ACC-DBS : change of quality of life by SF-36
Description
Efficacy of ACC-DBS will be evaluated by quality of life (SF36).
Time Frame
Day 0, Month 1, Month 4, Month 7, Month 10, Month 22
Title
Efficacy of ACC-DBS : change of quality of life by EQ-5D
Description
Efficacy of ACC-DBS will be evaluated by quality of life (EQ5D).
Time Frame
Day 0, Month 1, Month 4, Month 7, Month 10, Month 22

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: adult patients (age 18-70 years old) suffering from chronic (duration >1 year) unilateral neuropathic pain severe (VAS score >6/10) with high emotional impact (HAD subscores > 10) considered as resistant to medication specific to neuropathic pain at sufficient doses and durations (including at least antiepileptics and antidepressants) and not sufficiently improved by rTMS and relevant surgical solutions. Non inclusion criteria: previous history of stroke, cognitive impairment (MMSE score <24), DSMIV axis I psychiatric disorder, contra-indication to surgery, anesthesia or MRI; patient responder to rTMS,
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Denys FONTAINE
Organizational Affiliation
fontaine.d@chu-nice.fr
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of neurosurgery
City
Nice
ZIP/Postal Code
06000
Country
France

12. IPD Sharing Statement

Learn more about this trial

Combined Cingulate and Thalamic DBS for Chronic Refractory Chronic Pain

We'll reach out to this number within 24 hrs